Aspirin acute MI indication public education effort by FDA urged in Bayer comments.
This article was originally published in The Tan Sheet
Executive Summary
ASPIRIN ACUTE MI INDICATION PUBLIC EDUCATION EFFORTS BY FDA RECOMMENDED by Bayer Consumer Care in Sept. 11 comments on the agency's recently proposed professional labeling claim for aspirin. Published June 13, FDA's proposal would amend the tentative final monograph for OTC internal analgesic, antipyretic and antirheumatic drugs to include professional labeling of aspirin products for reduced "risk of vascular mortality in people with suspected acute myocardial infarction (MI)" ("The Tan Sheet" June 17, p. 3).